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OBJECTIVE—To determine whether interindividual heteroge-
neity in the erythrocyte (red blood cell [RBC]) transmembrane
glucose gradient might explain discordances between A1C and
glycemic control based on measured fructosamine.
RESEARCH DESIGN AND METHODS—We modeled the re-
lationship between plasma glucose and RBC glucose as the
concentration distribution (Ci-to-Co ratio) of a nonmetabolizable
glucose analog
14C-3-O-methyl glucose (
14C-3OMG) inside (Ci)
and outside (Co) RBCs in vitro. We examined the relationship
between that distribution and the degree of glycation of hemo-
globin in comparison with glycation of serum proteins (fruc-
tosamine), the glycation gap. A1C, fructosamine, and in vitro
determination of the
14C-3OMG distribution in glucose-depleted
RBCs were measured in 26 fasted subjects.
RESULTS—The Ci-to-Co ratio 0.89  0.07 for 3-O-methyl-D-
glucopyranose (3OMG) ranged widely (0.72–1.04, n  26). In
contrast, urea Ci-to-Co (1.015  0.022 [range 0.98–1.07], P 
0.0001) did not. Concerning mechanism, in a representative
subset of subjects, the Ci-to-Co ratio was retained in RBC ghosts,
was not dependent on ATP or external cations, and was reestab-
lished after reversal of the glucose gradient. The 3OMG Ci-to-Co
ratio was not correlated with serum fructosamine, suggesting
that it was independent of mean plasma glucose. However,
Ci-to-Co did correlate with A1C (R
2  0.19) and with the glycation
gap (R
2  0.20), consistent with a model in which differences in
internal glucose concentration at a given mean plasma glucose
contribute to differences in A1C for given level of glycemic
control.
CONCLUSIONS—The data demonstrate interindividual heter-
ogeneity in glucose gradients across RBC membranes that may
affect hemoglobin glycation and have implications for diabetes
complications risk and risk assessment. Diabetes 57:2445–
2452, 2008
A
1C is the current gold standard for determina-
tion of chronic glycemic control in people with
diabetes. Yet it is common to ﬁnd hematologi-
cally normal people with diabetes in whom A1C
appears discordant from other measures of glycemic con-
trol. Some have suggested the notion of a “hemoglobin
glycation index” to assess A1C discordance from mean
blood glucose (1–3). We have quantitated this discordance
with the use of the glycation gap (GG), a measure of the
disparity between two integrated measures of glycemic
control, one intracellular in red blood cells (RBCs), A1C,
and the other extracellular, glycated serum protein (GSP)
measured as fructosamine (4). A non-zero GG could result
from differences between the ambient glucose concentra-
tions or rates of glycation in the intracellular and extra-
cellular compartments, and/or interindividual differences
in the turnover/metabolism of underlying proteins. We
have demonstrated that the GG is reproducible within
subjects over time and is associated with important clini-
cal end points. In longstanding type 1 diabetes, there is a
over a twofold rise in prevalence of nephropathy in
patients with high GG versus low GG (4). GG is also a
predictor of retinopathy (5). Furthermore, approximately
one-third of the heritable component of A1C (6) is shared
in common with a heritable component of the GG (7),
suggesting a genetically determined mechanism for discor-
dance between fructosamine and A1C.
As indicated by Higgins et al. (8), two factors other than
plasma glucose inﬂuence the level of glycated hemoglobin:
lifespan and “glucose permeability” of the RBC. Yet there
has been little systematic investigation of how interindi-
vidual variability in these parameters may affect the rela-
tionship between measured A1C levels and plasma
glucose. In another study, we examined differences in RBC
survival and reported variability that can produce signiﬁ-
cant deviations of A1C from expected values (9). We focus
here on glucose permeability, i.e., the concentration of
glucose within versus outside the RBC. Glucose transport
across the RBC membrane mediated by the GLUT1 trans-
porter is complete within seconds at body temperature
(10). Thus, in addition to plasma glucose and RBC lifes-
pan, “equilibrium” intracellular glucose, rather than the
rate of glucose transport, is likely the determining factor in
hemoglobin glycation.
Over 80 years ago, Somogyi (11) found that the “corpus-
cular sugar–to–serum sugar” ratio averaged 0.77. Although
it varied among healthy subjects between 0.66 and 0.95,
the ratio did not change with glucose challenge and was
similar between a diabetic and nondiabetic subject. In the
Higgins et al. (8) description of the variation in A1C
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of the RBC, the erythrocyte glucose–to–plasma glucose
concentration ratio was 0.67  0.14, demonstrating greater
variation than expected for experimental technique or
RBC water space, which is very tightly regulated (mean
corpuscular hemoglobin concentration [MCHC] range 32–
35%) (12). This suggests the possibility of substantial
interindividual variation in erythrocyte glucose. Similarly,
Gould and Yudkin and coworkers (2,3) reported system-
atic variation in the relationship between A1C and fasting
plasma glucose in a nondiabetic population that correlated
with erythrocyte glucose. A signiﬁcant difference in eryth-
rocyte glucose–to–plasma glucose concentration ratio was
found under non–steady state conditions: 0.74  0.12 in
“low glycators” and 0.98  0.06 in “high glycators” (P 
0.01) (3) after accounting for cell water (B. Gould, per-
sonal communication). The similarity among the results of
Somogyi, Higgins et al., and Gould et al. are sufﬁcient to
propose that there are individual differences in how sugar
distributes into the RBC. Yet, one of the key assumptions
in the assessment of glycemic control by A1C is that
glucose in the intra-erythrocyte space (which determines
hemoglobin glycation) bears a common relationship to
glucose in the plasma space (which deﬁnes glycemic
control). A systematic difference in glucose permeability
would constitute a source of intersubject differences in
A1C at a given average plasma glucose concentration.
In this study, we sought to test the hypothesis that
interindividual heterogeneity of the intracellular-to-extra-
cellular glucose ratio contributes to variability in the
relationship of A1C to fructosamine. We conﬁrmed the
existence of a glucose gradient across the human RBC
membrane by measuring the distribution of the nonme-
tabolizable glucose analog,
14C-3-O-methyl glucose (
14C-
3OMG) into the RBC, which eliminated the potential
contribution of metabolism of glucose to such measure-
ments. We validated our methodologies by demonstrating
the expected equilibration of another small molecule,
urea, and eliminated intracellular hemoglobin, ATP, and
transmembrane cation gradients as contributors to the
glucose gradient. Finally, we demonstrate that the varia-
tion of the transmembrane glucose gradient among indi-
viduals correlates with the glycation gap and A1C but not
with fructosamine.
RESEARCH DESIGN AND METHODS
3-O-methyl-D-glucopyranose (3OMG), 3-O-(
14C-methyl)-D-glucose, mercuric
chloride, phloretin, cytochalasin B, Drabkin’s reagent, and hemoglobin stan-
dards were obtained from Sigma Chemical (St. Louis, MO). PBS, perchloric
acid, Scintisafe Plus cocktail, and STANBIO cyanmethemoglobin standards
were from Fisher Scientiﬁc (Pittsburgh, PA).
Subjects recruited were 14 years of age (Table 1). Exclusion criteria
included baseline serum creatinine 1.5 mg/dl, urine albumin 200 g/min
(timed collection) or 179 g/mg creatinine (spot collection), transaminases
more than three times the upper limit of normal, New York Heart Association
heart failure stage 3, hematocrit 34%, reticulocyte count 2%, evidence of
hemoglobinopathy on high-performance liquid chromatography (HPLC) anal-
ysis of hemoglobin, active infection, or an underlying illness known to be
associated with body wasting (e.g., malignancies or tuberculosis). All research
procedures were approved by the University of Cincinnati Institutional
Review Board.
Preparation of erythrocytes and ghosts. Blood was drawn in heparin-
coated tubes and processed as previously described (13) with modiﬁcations
from Klepper et al. (14). Blood specimens were centrifuged at 2,500 rpm for 5
min to sediment RBCs. Serum and buffy coat were aspirated. To minimize
differences in cellular sugar transport experiments resulting from diabetic
subjects’ plasma glucose in vivo, erythrocytes were incubated at 37°C twice
for 30 min in a 10-fold excess of PBS, then washed twice in PBS at ice
temperature. Assays were standardized by measurement of hemoglobin
spectrophotometrically with Drabkin’s or Stanbio reagents and adjusting all
erythrocyte suspensions to hemoglobin 15 g/dl for 3OMG transport. To
prepare pink ghosts, packed RBCs were lysed in 10 volumes of 5 mmol/l
phosphate buffer, pH 7.5. For white ghosts, erythrocytes were lysed in 50 V of
the hypotonic buffer. Ghosts were centrifuged; pink ghosts were washed twice
with cold PBS, and white ghosts were washed with lysis buffer until the
supernatant was clear. For the depletion of intracellular ATP, 8 units/ml of the
enzyme apyrase was included in the lysis buffer. Ghosts were resealed with
150 mmol/l KCl in lysis buffer at 37°C for 1 h. Resealed ghosts were
sedimented, the supernatant was aspirated, and the ghosts were decanted (to
remove the nonlysed cell button adhering to the bottom of the centrifuge
tube) and subjected to an additional wash/centrifugation cycle. The resulting
cells are impermeable to
14C-maltose (the 3OMG-to-maltose space ratio of
RBC ghosts is 100:1) (15).
Erythrocyte membrane glucose gradient in vitro methods. Erythrocyte
membrane glucose gradient in vitro methods were developed from those used
for zero-trans glucose inﬂux kinetics (10,14,16,17). 3OMG, which undergoes
phosphorylation several orders of magnitude more slowly than glucose and is
virtually nonmetabolizable (18–20), has been used extensively in glucose
transport studies (10). Aliquots of erythrocytes (100 l), prepared as above,
were suspended in 200 l
14C-labeled (0.5 Ci/ml ﬁnal) and unlabeled 3OMG,
yielding a ﬁnal concentration of 10 mmol/l for single Ci-to-Co ratio determi-
nations, or 0.3–20 mmol/l to measure Ci-to-Co ratio versus 3OMG. Incubations
were stopped by the addition of ice-cold stop solution consisting of 50 mol/l
phloretin and 100 mol/l mercuric chloride in PBS at various time points. Zero
time values were obtained by the addition of stop solution to the RBC
suspension before addition of
14C-3OMG. Cells were centrifuged at 14,000 rpm
for 30 s, and 100-l aliquots of the supernatant were removed to sample
extracellular counts. The RBC pellet was washed twice with stop solution on
ice and then lysed with 0.5 ml 3% perchloric acid. After centrifugation at 14,000
rpm for 10 min at room temperature, 200-l aliquots of the perchloric acid
extract were collected to sample intracellular counts. After scintillation
counting, the concentration of
14C-3OMG (in counts per minute per milliliter)
outside the cell (Co) and inside the cell (Ci) was then calculated. Ci was
determined as counts per minute per milliliter cell water. Assuming identical
internal- and external-speciﬁc activities, the ratio counts of Ci to Co would
then be equivalent to the ratio of inside to outside concentrations of unlabeled
compound.
An alternative indirect method was developed for comparison of Ci to Co
for
14C-3OMG and
14C-urea (ﬁnal unlabeled urea, 2 mmol/l). Tracer was added
to RBC suspensions adjusted to 15 g/dl hemoglobin (45% hematocrit) and
incubated to steady state. After centrifugation, aliquots of supernatant and
14C-tracer stock solution were counted for radioactivity. From the supernatant
and stock solution counts, the hematocrit, and the cell water fraction
estimated from MCHC, the concentration of counts in cell water Ci and the
corresponding Ci-to-Co ratio were calculated.
Results are reported as the mean of triplicate measurements. In represen-
tative experiments, there was no change in the hematocrit from the beginning
TABLE 1
Study subject characteristics
Age (years) 44  11
N 26
Sex
Female 13
Male 13
Glucose tolerance status and
diabetes treatment
Nondiabetic 5
Type 1 diabetic 10 (all insulin only)
Type 2 diabetic 11 (6 insulin, 7 metformin,
2 sulfonylurea, 4
thiazolidinediones)
Race (n)
Caucasian 20
African American 5
South Asian 1
Glycemic control
Fasting plasma glucose (mg/dl) 168  76 (56–309)
A1C (%) 7.6  2.1 (4.6–12.4)
Fructosamine (mol/l) 322  82 (191–505)
Data are means  SD and means  SD (range) unless otherwise
indicated.
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absorbance; no difference in hemolysis between 3OMG and urea incubations).
Calculation of cell water. The cell water was calculated for each sample
from the MCHC determined on a complete blood count sent simultaneously to
the clinical laboratory according to the following equation (21):
(1  CWFsample)  (1  CWFreference)  MCHCsample/MCHCreference
where cell water fraction (CWF)reference was measured as 0.669 (volume of
solvent water per volume of cells) on a sample of normal cells with measured
MCHCreference  33.5 g/dl. In preliminary experiments, CWF was determined
experimentally on several blood samples and was comparable with that
calculated by MCHC.
Analytic methods. A1C was measured using HPLC ion exchange (Tosoh,
Tokyo, Japan) (interassay coefﬁcient of variation [CV] 2.9% at A1C 5.5% and
1.9% at A1C 10.0%). Fructosamine was measured at Quest Diagnostics by
autoanalyzer (Roche Diagnostics) with a nitroblue tetrazolium reaction,
interassay CV 2% (4).
Statistical analysis. The GG was computed based on a reference regression
line relating A1C and fructosamine as previously reported (4). All data are
reported as means  SD, unless otherwise indicated. We used Pearson’s
correlation coefﬁcients and linear regression to evaluate relationships be-
tween variables. Analyses were conducted using SPSS version 15.0 (SPSS,
Chicago, IL) and JMP (SAS Institute, Cary, NC).
RESULTS
Evidence for a glucose concentration gradient in
human erythrocytes under conditions of steady state.
Human erythrocytes incubated with a series of concentra-
tions of 3OMG rapidly reached a steady state within 5 min
at 37°C (Fig. 1A). This was stable well beyond the 60-min
time point chosen for ongoing comparative analysis (data
not shown). However,
14C-3OMG inside (Ci) and outside
(Co) the cell did not equalize, and the Ci-to-Co ratio at
steady state at 37°C departed signiﬁcantly from unity.
Ci-to-Co increased with increasing 3OMG (Fig. 1B), but the
glucose gradient expressed as the difference between
inside and outside was actually higher at higher concen-
trations. Ci-to-Co measured at physiological concentra-
tions of 10 mmol/l 3OMG was 1 in 25 of 26 subjects, with
a broad distribution of values (0.89  0.07) (Fig. 1C). For
determinations of Ci-to-Co on fresh samples assayed over
a 12-day period, within subject CV ranged from 5 to 7%.
There was no correlation of Ci-to-Co with mean corpuscu-
lar volume (MCV) or MCHC.
Comparison of 3OMG and urea gradients. To test
whether the transmembrane asymmetry would also be
observed with a distinct small molecule thought to ﬁll the
RBC water space, parallel incubations were conducted
simultaneously with
14C-3OMG and
14C-urea, each in qua-
druplicate (Fig. 2). Since rapid efﬂux of urea from RBC
precluded washing of cells, Ci for both compounds in
these studies was calculated from measured counts in the
14C-labeled stock solution added to the suspension and in
the supernatant representing the extracellular space (see
RESEARCH DESIGN AND METHODS). A wide distribution and
departure from unity of 3OMG Ci-to-Co ratios is apparent,
conﬁrming the previous observation (Fig. 1C). In contrast,
urea Ci-to-Co was tightly clustered at 1.015  0.022. The
calculations of Ci for both 3OMG and urea used the same
estimates of cell volume, MCHC, and cell water; therefore,
the Ci-to-Co ratio of unity for urea validates these esti-
mates. In eight subjects, Ci-to-Co ratios were assessed
using both direct and indirect measures for
14C-3OMG,
along with simultaneous measurement of the
14C-urea
concentration ratio (indirect) on the same blood samples.
The results were signiﬁcantly lower (P  0.0001 each;
paired t test) for
14C-3OMG with both the direct (0.93 
0.02) and indirect methods (0.86  0.05) compared with
14C-urea (1.04  0.04). Ci-to-Co ratios for
14C-glucose,
14C-galactose, and
14C-2-deoxy-glucose were similar to
those with
14C-3OMG (data not shown), providing conﬁr-
mation among a series of sugars transported by GLUT1.
These results are consistent with previous ﬁndings that the
“nonsolvent” water compartment in red cells is very small,
i.e., all the water of RBCs is available as solute for small
A
B
C
FIG. 1. A: Time course of
14C-3OMG uptake into glucose-depleted
human erythrocytes at 37°C at a series of initial external sugar
concentrations. Values shown are mean of triplicate incubations. B:
Dependence of the 3OMG gradient on external 3OMG. The concentra-
tion gradient decreases (i.e., Ci-to-Co approaches 1) with increasing
3OMG across a concentration range broader than the physiologic (n 
7; different symbols and lines denote individual subjects). C: Distri-
bution of Ci-to-Co determined at steady state in human subjects
(Table 1).
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results for glucose (22). Thus, Ci-to-Co ratios 1 are not
due to variations or error in estimation of water content of
the cells.
Transmembrane gradient is maintained in RBC
ghosts. Some studies in the literature suggest that the high
concentration of hemoglobin may “compartmentalize” glu-
cose, generating an apparent 3OMG gradient (23). To test
this possibility, Ci-to-Co determinations were conducted in
“pink” and “white” ghosts of red cells. Pink ghosts repre-
sent the resealed product of lysing red cells in a 10-fold
excess of 5 mmol/l sodium phosphate hypotonic buffer,
reducing the MCHC from 33.3 to 1.6–2.6 g/dl; white ghosts
result from conducting analogous lysis in a 50-fold excess
of hypotonic solution, further reducing MCHC to 0.011–
0.037 g/dl. These procedures raise the CWF from 0.675 to
0.973 and 0.99, respectively. Preparation of each ghost
form did not result in disappearance of the Ci-to-Co
gradient (both Ci and Co measured directly using stop
solution). In fact, the Ci-to-Co gradient became more
pronounced (Fig. 3A and B). This excludes hemoglobin as
a source of the Ci-to-Co gradient.
Effect of perturbing energy status on observed gra-
dient. The Ci-to-Co gradient was not dependent on the
normal cellular Na/K gradient. Cells incubated in either
isotonic NaCl or isotonic KCl had identical Ci-to-Co gradi-
ents (Fig. 4A). The Ci-to-Co gradient was also not depen-
dent on ATP. Figure 4B demonstrates that Ci-to-Co was the
same in ghosts made with and without the ATP-destroying
enzyme apyrase, which is present during resealing.
Testing for an “impurity” in the labeled 3OMG. Qual-
ity control analysis on the
14C-3OMG provided by the
manufacturer using HPLC indicated a homogeneous spe-
cies. It could be hypothesized that another molecular
species that fails to cross the red cell membrane, e.g., an
enantiomer, might not be detected by that technique,
giving rise to an artifactual 3OMG Ci/Co gradient (24,25).
We chose a functional approach to test for such an
impurity in the tracer. If a nontransportable impurity were
responsible for the Ci-to-Co gradient, incubation with
RBCs would result in uptake solely of transportable “pure”
tracer. Incubation of those cells with fresh tracer-free
medium would then elute the tracer from the cells and
result in an “impurity-depleted” eluate. Subsequent incu-
bation of fresh RBCs with this impurity-depleted eluate
should therefore eliminate the Ci-to-Co gradient, if the
impurity were the source of the apparent gradient. There-
fore, a standard zero-trans experiment was performed
with and without the following modiﬁcation: the superna-
tant from the initial incubation for 1 h was removed by
centrifugation and replaced with 200 l fresh tracer-free
medium for 60 min at 37°C. This medium (termed the
“eluate”) was then separated from the cells by centrifuga-
tion, and 200 l was added to a fresh suspension of 100 l
RBCs in 10 mmol/l 3OMG. Similar Ci-to-Co gradients were
observed with medium containing fresh unmodiﬁed tracer
(0.92  0.01) and with the eluate (0.91  0.04, n  11, P 
NS) whose tracer had to have been able to enter and then
exit from cells to which it had previously been exposed.
This indicates that a nontransportable impurity is unlikely
to account for the deviation of the Ci-to-Co ratio from 1.0.
Effect of reversal of initial glucose gradient. The
previous experiments represented inﬂux of glucose into
the cell down an outside-to-inside concentration gradient.
We attempted to reverse this gradient by ﬁrst equilibrating
cells in
14C-3OMG with 0.2 mmol/l 3OMG and then expand-
ing the extracellular space with an equal volume of sugar-
free buffer (which thereby dilutes the extracellular sugar
concentration from 0.2 to 0.1 mmol/l) to examine the
steady-state gradient achieved when ﬂux is in the opposite
direction. The lower concentration of 3OMG was used to
allow for studying the effects of cytochalasin B, a well-
documented inhibitor of GLUT1-mediated glucose trans-
3OMG UREA
0.75
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0.95
1.05
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FIG. 2. Paired values of the Ci-to-Co ratio determined for 3OMG vs.
urea within subject are different (P < 0.0001). The Ci-to-Co ratio
approximates unity and has a narrow distribution for urea in all
subjects but is below unity and more heterogeneous in the same
population for 3OMG.
A
B
FIG. 3. 3OMG (3-O-methyl-glucose) Ci-to-Co dependence on external
3OMG in pink (PG) (A) and white (WG) (B) erythrocyte ghosts
compared with intact RBCs (S1–S5 denote different human subjects).
The 3OMG concentration gradient was not reduced, and in fact was
more pronounced as hemoglobin decreased. A is representative of 17
experiments in eight subjects, and B is representative of one experi-
ment in each of three subjects.
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gradient, the ﬁnal steady-state Ci-to-Co ratio was not
signiﬁcantly altered (Fig. 5) and there was no effect of
incubation with cytochalasin B (data not shown). This
ﬁnding is striking, in that cellular glucose concentration
falls below extracellular glucose concentration. We do not
have a mechanistic explanation for this phenomenon,
given the independence of Ci-to-Co ratios from ATP and
cation gradients. However, this ﬁnding suggests that the
Ci-to-Co gradient would persist in vivo, tracking changes in
plasma glucose concentrations whether rising or falling
(see DISCUSSION).
Relationship of A1C and GG with Ci-to-Co ratio.
Ci-to-Co ratio, which varied among individuals, correlated
positively and signiﬁcantly with both A1C and GG (Fig. 6).
Higher A1C levels were associated with higher Ci-to-Co
ratios. Likewise, individuals with higher Ci-to-Co ratios had
higher GG values, i.e., when the intra-erythrocyte concen-
tration of sugar was higher relative to extracellular sugar
(represented by higher Ci-to-Co ratios), so was the glyca-
tion of the intracellular protein hemoglobin in comparison
with the glycation of extracellular proteins (reﬂected in
higher GG). This is consistent with variation in the Ci-to-Co
ratio among individuals contributing to A1C levels and to
the discordance between A1C and glycemic control. In
contrast, there was no correlation of either Ci-to-Co or GG
with serum fructosamine (Table 2), indicating that Ci-to-Co
and GG were not inﬂuenced by glycemic control per se. In
statistical terms, the GG is the residual of the regression of
A1C on fructosamine. It should be randomly distributed
with respect to fructosamine, hence, as observed, not
correlated with fructosamine. On the other hand, GG
would be expected to correlate with A1C because a high
GG suggests that the A1C is higher than would be pre-
dicted and a low GG suggests that the measured A1C is
lower than predicted from fructosamine. The correlation
of Ci-to-Co with GG is consistent with the GG being
determined in part by the Ci-to-Co ratio.
DISCUSSION
The key ﬁndings in this study are that 1) at steady state,
there is a sugar concentration gradient across the human
erythrocyte membrane that varies between individuals; 2)
the gradient is not dependent on glucose metabolism,
hemoglobin concentration, ATP, or the transmembrane
cation gradient; 3) the glucose gradient correlates with
A1C but is not related to a non-RBC glycated protein
measure of glycemic control, suggesting that it reﬂects an
inﬂuence on A1C unrelated to plasma glucose. Taken
together, these data are consistent with the hypothesis
that variability in the intracellular (erythrocyte glucose)
relative to extracellular glucose signiﬁcantly contributes
to interindividual variation in A1C. This has direct impli-
cations for the mechanisms determining A1C and its
clinical interpretation as a measure of glycemic control
and risk prediction.
Although use of a nonphysiologic sugar to exclude the
effects of glucose metabolism and deﬁned media are
potential limitations to generalizability in vivo, results
were similar with physiologic sugars. We eliminated a
smaller distribution space for glucose in the RBC than the
cell water volume estimated from the MCHC as a potential
explanation of a steady-state transmembrane glucose gra-
dient. Cell water volume estimated from MCHC and vali-
A
B
FIG. 4. A: Effect of transmembrane cation gradient on the 3OMG
Ci-to-Co dependence on external 3OMG. The dependence of 3OMG
Ci-to-Co on 3OMG was compared in extracellular medium containing
137 mmol/l KCl vs. the standard PBS containing 139 mmol/l NaCl. The
use of KCl buffer failed to overcome the gradient. The data are
representative of one experiment from each of three subjects. B: ATP
effects. Preparations of pink ghosts (PG) sealed with the addition of
the enzyme apyrase to deplete intracellular ATP failed to shift Ci-to-Co
toward unity. However, the preparation of ghosts reduced the 3OMG
dependence of the Ci-to-Co ratio and was further reduced by apyrase.
The data are representative of one experiment in each of four subjects.
FIG. 5. Membrane gradient reversal. In this experiment, RBCs were
ﬁrst incubated with 3OMG until an apparent steady-state outside-to-
inside gradient was reached. Next, the samples (arrow) were diluted
twofold to expand the extracellular volume. If the observed gradient
was due to a failure to reach true equilibrium, then the gradient would
be expected to reverse after dilution. However, after dilution, there
was a prompt reestablishment of essentially the same steady-state
outside-to-inside gradient, indicating that the sugar moved up a con-
centration gradient. The data are representative of one experiment in
each of 15 subjects.
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long-standing observation that virtually all water in RBCs
was available for solvation of small molecules (28,29).
More recently, Bookchin et al. (22) showed that even the
water contained in the highly structured dense protein
domain of intracellular polymerized hemoglobin S was
accessible to small molecules, including glucose. Further-
more, the Ci-to-Co gradient did not depend on high intra-
cellular hemoglobin concentrations. The presence of
intracellular membrane vesicles could conceivably repre-
sent a compartment inaccessible to glucose. Such endo-
cytic vesicles have been demonstrated in sickle RBCs but
not in normal RBCs (30). Thus, there is no evidence in
RBCs for a substantial water compartment inaccessible to
glucose that could explain Ci-to-Co ratios 1.
Another potential explanation of the failure of glucose
concentrations to equilibrate across the membrane is that
kinetic characteristics of the glucose transport system
limits transport before equilibration occurs, i.e., glucose
inﬂux is shut down before equal concentrations are
reached. However, the reestablishment of Ci-to-Co when
external glucose concentrations were diluted (Fig. 5) is
inconsistent with this mechanism. This experiment in fact
suggests a third possibility: a mechanism for net export of
glucose from the cell. There has been no evidence to date
for active transport of glucose in or out of the RBC, and
the Ci-to-Co gradient was not dependent on ATP or cation
gradients that might serve as energy sources; there is not
an obvious alternative candidate in the artiﬁcial media
used for these 3OMG uptake experiments. Other mole-
cules share the GLUT1 transporter (31,32), but competi-
tion is unlikely in the artiﬁcial media used, especially given
the wide concentration range over which the sugar Ci-
to-Co gradient is preserved (Fig. 1B). Nevertheless, there
are a number of aspects of the glucose transport system
that suggest more complex characteristics and regulation
than that of a simple “facilitated diffusion” mechanism.
Red cell sugar transport displays kinetic asymmetry in
which Vmax and Km for sugar exit are greater than Vmax and
Km for sugar entry (16,17,33–35). This does not result in
net glucose export when intracellular sugar  extracellu-
lar sugar because the ratio of Vmax to Km for net exit and
entry are identical (36). Nevertheless, the transient fall in
3OMG concentration below external concentrations has
been seen in rapid counter-ﬂow studies, and the rapid
3OMG exit observed in human RBCs and ATP-containing
RBC ghosts (A.C. and J.M. Leitch, unpublished observa-
tions) supports this alternative possibility that RBCs con-
tain a second glucose transport system that actively
exports sugars (37). The identity of the putative glucose
exporter is not known (37), and the energy source driving
glucose exit is unclear.
As has recently been indicated, the GG (or the analo-
gous hemoglobin glycosylation index) (1,38–40) is not
independent of A1C (41,42). It does however allow quan-
titation of sources of variation in A1C (43). In this con-
struct, in which the GG is deﬁned as the difference
between measured and predicted A1C, the Ci-to-Co ratio
is linked not only to A1C but also with the fraction of the
variance in A1C that is not shared in common with the
integrated extracellular measure of glycemic control,
fructosamine.
Whatever the molecular mechanism involved in estab-
lishing the glucose gradient of RBCs, the observed varia-
tion among individuals in Ci-to-Co ratios from 0.7 to 1.0,
could lead to substantial differences in hemoglobin glyca-
tion for a given plasma glucose, with signiﬁcant clinical
implications. Critical clinical decisions are made based on
A1C in the 6–8% range (44–48). The difference between
one individual with a Ci-to-Co of 0.75 and another with
Ci-to-Co of 0.99 could be an 25% difference in the level of
hemoglobin glycation for a given mean plasma glucose,
which translates to a difference of 1.5–2.0 A1C percentage
points. We speculate that the interindividual variation in
A
B
FIG. 6. A1C (A) and GG (B) rise as the
14C-3OMG Ci-to-Co ratio
increases. The GG is a measure of variance in A1C relative to glycated
serum proteins. Across the population, intracellular sugar rises rela-
tive to extracellular, as does hemoglobin glycation relative to the
glycation of extracellular proteins. Values of r
2 are shown to demon-
strate the fraction of the variance in A1C and GG accounted for by
Ci-to-Co ratio. In contrast (Table 2), fructosamine has no signiﬁcant
slope relative to Ci-to-Co ratio.
TABLE 2
Correlation coefﬁcients (r) and P values between A1C, fruc-
tosamine, GG, and Ci-to-Co ratio*
rP
A1C vs. fructosamine 0.77 0.001
A1C vs. GG 0.76 0.001
GG vs. fructosamine 0.17 0.40
Ci-to-Co vs. A1C* 0.44 0.025
Ci-to-Co vs. GG 0.45 0.023
Ci-to-Co vs. fructosamine 0.23 0.26
*Ratio of sugar concentration inside to outside measured as
14C-
3OMG CPM inside vs. outside (see Fig. 6 legend).
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in the incidence of diabetes complications. It will be
important to understand whether the phenomenon we are
describing in RBCs extrapolates to other cell types, nota-
bly endothelial cells. If so, then the Ci-to-Co glucose gradient
may have implications not only for A1C, but also for those
intracellular glucose concentrations that affect the rate of
progression of diabetes complications themselves.
In conclusion, we have identiﬁed a variable in the
RBC—the trans-membrane glucose gradient—that is a
strong candidate to introduce interindividual variability
into the rate of A1C formation. Recognizing this variable
has important implications for clinical interpretation of
this widely used test. Understanding the underlying mech-
anism may have fundamental implications for interindi-
vidual variation in the frequency of diabetes complications
in relation to apparent glycemic control.
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